Citi analyst Andrew Baum raised the firm’s price target on Merck to $135 from $130 and keeps a Buy rating on the shares. The analyst says Merck’s “sure-footed deal-making is diminishing the hurdle” of the anticipated Keytruda loss of exclusivity in 2028-2031.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck: FDA approves Keytruda in combination with gemcitabine and cisplatin
- Merck reports KEYNOTE-564 trial met its key overall survival secondary endpoint
- Roblox upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- Merck upgraded to Outperform from Market Perform at BMO Capital
- Options Volatility and Implied Earnings Moves Today, October 26, 2023